IN8bio Share Price

IN8bio Share Price

NASDAQ: INAB | Micro Cap | Healthcare
$0.79
-$0.03 (-3.66%) Last updated on 18 Nov, 2026 | 20:57 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Corporate Actions
  • About
  • Price history
  • FAQs

IN8bio Stock Performance

Open
$0.80
Prev. Close
$0.82
Circuit Range
N/A
Day Range
$0.79 - $0.80
Year Range
$0.75 - $2.71
Volume
200
Average Traded
$0.80

IN8bio Share Price Today

As of 19 November 2026, IN8bio, Inc.'s share price is $0.79. The stock opened at $0.80, compared to its previous close of $0.82. During today's trading session, IN8bio, Inc.'s share price traded between $0.79 and $0.80, with an average price of $0.80. Over the past 52 weeks, the stock has recorded a high of $2.71 and a low of $0.75. In terms of performance, IN8bio, Inc.'s share price has declined by 57.75% over the last six months and is down 60.67% on a year-on-year basis.

IN8bio Share Price Chart

Line chart of the IN8bio price trend over the selected period. The price fell overall, ranging from 0.79 to 0.80, ending at 0.79.
$0.79$0.80
L
Show Current Price
H

IN8bio Stock Fundamentals & Key Indicators

Market Cap
$3.46M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-1.80
Revenue (TTM)
$0.00
Return On Equity (TTM)
-136.91%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-24.16%

IN8bio Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$3.85-$4.94-$5.09-$4.78
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-28.31%-3.04%6.09%

IN8bio Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.00$0.00$0.00
Net Profit-$28.52-$30.01-$30.44-$19.44
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-5.22%-1.43%36.14%

IN8bio Balance Sheet

All figures in USD Million

Particulars2025202420232022
Non Current Assets4.48.379.0810.81
Current Assets27.8812.5824.6322.23
Total Assets32.2820.9433.7133.04
Non Current Liabilities1.563.383.384.49
Current Liabilities3.163.085.395.82
Total Liabilities4.726.478.7710.31
Shareholders' Equity27.5614.4824.9422.73

IN8bio Cash Flow

Annually

All figures in USD Million

Particulars2025202420232022
Operating-12.71-24.15-23.34-24.12
Investing0.0-0.19-0.6-3.71
Financing28.6414.1827.048.99

Corporate Actions

Split
Ex-date: 06 Jun 2025

About IN8bio

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

IN8bio Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$0.96
$0.79
-14.04%
Oct 2026
$1.45
$0.92
-28.48%
Sep 2026
$1.11
$1.28
+31.12%
Aug 2026
$0.95
$0.98
-15.52%
Jul 2026
$1.43
$1.16
-18.60%
Jun 2026
$1.80
$1.43
-23.80%
May 2026
$1.50
$1.87
+26.35%
Apr 2026
$1.40
$1.48
+1.37%
Mar 2026
$1.73
$1.46
-14.37%
Feb 2026
$1.94
$1.71
-13.45%
Jan 2026
$2.32
$1.97
-15.81%
Dec 2025
$2.06
$2.34
+16.48%

IN8bio Share Price FAQs